Poised
for Growth
RPI has devised a three-fold business strategy to ensure the
future growth of its generics, branded and OTC business. It
includes a combination of
 |
Organic growth |
|
|
In-licensing |
|
Acquisitions |
Ranbaxy Pharmaceuticals Inc. (RPI) has established growth
plans for its generics business with a well-defined pathway
for ANDA submissions over the next several years. RPI is also
focusing on securing products and services through strategic
alliances with other companies and bringing in products with
complex formulations which may present entry barriers for
other companies. This strategy will enable RPI to reach the
market with select generic products well before other competitors.
The company is also executing plans to challenge the intellectual
property of several existing branded products by producing
these products using processes that do not infringe on patents.
Using its vertical integration capabilities and continuous
market monitoring, the company is developing "niche"
products.
Through RLI, Ranbaxy has introduced a number of branded products
that offer distinct advantages to patients and medical professionals
over existing products, such as more convenient dosage forms
or products that are easier to administer. With its well-defined
business strategy, Ranbaxy looks forward to a future of continued
growth and success.
|
